Francisca Bartilotti Matos

Francisca Bartilotti Matos

Auto-generated profile, based on publicly available information

Francisca Bartilotti Matos

Infectious Diseases Department, Unidade Local de Saúde de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2022 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
SSSophie Schneitler
Sophie Schneitler
JSJonas Seebacher
Jonas Seebacher
FMFrancisca Bartilotti Matos
Francisca Bartilotti Matos
IAIrem Aktar
Irem Aktar
PLPhilippa Lantwin
Philippa Lantwin
RJRosemary James
Rosemary James

1 November 2024 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
FMFrancisca Bartilotti Matos
Francisca Bartilotti Matos
DMDara Mbanze
Dara Mbanze
PGPerpétua Gomes
Perpétua Gomes
CFCristóvão Figueiredo
Cristóvão Figueiredo
DCDaniel Coutinho
Daniel Coutinho
LMLuís Malheiro
Luís Malheiro
Resistance to antiretroviral therapy is an increasing challenge in the management of HIV. We present the case of a woman living with HIV, with a history of multiple treatment regimens and resistances to antiretrovirals, who has been successfully treated with a combination of lenacapavir and fostemsavir for the past year, obtaining an undetectable viral load within one month of starting therapy and reporting no serious side effects. This case is amongst the first to document the combined use of lenacapivir and fostemsavir in treating multidrug-resistant HIV. It supports the potential of these novel agents in managing complex cases of HIV resistance.

13 August 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
FMFrancisca Bartilotti Matos
Francisca Bartilotti Matos
PDPeter Davies
Peter Davies

12 September 2024 in Cureus
Verified
Journal Article
Open access
PDF file
FMFrancisca Bartilotti Matos
Francisca Bartilotti Matos
MRMafalda Ribeirinha
Mafalda Ribeirinha
RSRui Salvador
Rui Salvador
JFJoana Fragoso
Joana Fragoso
LMLuís Malheiro
Luís Malheiro
Nongonococcal urethritis is a very common infection in men. Though Streptococcus pyogenes has frequently been associated with other genital tract infections, it has very rarely been reported as a causative agent of urethritis. We report a case of a healthy 31-year-old man who presented to the emergency department with symptoms of urethritis and penile ulcers. Culture of both urine and urethral exudate were positive for S. pyogenes sensitive to penicillin. A swab of the ulcer was positive for herpes simplex virus 2. He was treated with a seven-day course of amoxicillin and acyclovir, with full resolution of symptoms. To the best of our knowledge, this is the first case report of S. pyogenes urethritis transmitted through sex between men. This organism is a possible and probably underreported agent of urethritis. This case underscores the importance of microbiological testing in the treatment of urethritis.

17 July 2026 in AIDS and Behavior
Verified
Journal Article
Open access
PDF file
HGHelder Gemo
Helder Gemo
AGAna Gorgulho
Ana Gorgulho
FBFrancisca Bartilotti
Francisca Bartilotti
DMDara Mbanze
Dara Mbanze
CFCristóvão Figueiredo
Cristóvão Figueiredo
LMLuis Malheiro
Luis Malheiro
HIV-related stigma remains a barrier to well-being and long-term care despite effective antiretroviral therapy. We conducted a cross-sectional analysis using baseline data from a prospective real-world cohort of adults receiving routine HIV care in northern Portugal. Overall HIV stigma was the primary outcome, and associations with sociodemographic, clinical, laboratory, behavioral, and patient-reported variables were examined using univariable and multivariable linear regression. Among 467 participants, the median overall stigma score was 30 (Q1–Q3, 26–35), and disclosure concerns had the highest median subscale score. The multivariable model was statistically significant, F(7,429) = 10.254, p < 0.001, adjusted R² = 0.129. Higher overall stigma was independently associated with HIV-1 viral load ≥ 200 copies/mL (B = 4.489, 95% CI 0.660 to 8.318, t = 2.304, p = 0.022), anxiety symptoms (B = 0.318 per point, 95% CI 0.120 to 0.515, t = 3.166, p = 0.002), and depressive symptoms (B = 0.236 per point, 95% CI 0.031 to 0.441, t = 2.259, p = 0.024). A history of opportunistic infection was associated with lower stigma (B = -1.826, 95% CI -3.524 to -0.128, t = -2.114, p = 0.035). Higher quality-of-life scores were consistently associated with lower stigma (t values ranging from − 10.690 to -4.161, all p < 0.001). These findings support routine stigma-sensitive and psychologically informed HIV care to identify psychosocial needs and potentially improve well-being and treatment outcomes.

1 January 2026 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
MDMaria Donga
Maria Donga
AGAna Gorgulho
Ana Gorgulho
FBFrancisca Bartilotti
Francisca Bartilotti
DMDara Mbanze
Dara Mbanze
RMRita Menezes
Rita Menezes
LMLuis Malheiro
Luis Malheiro
Background: Pneumococcal urinary antigen testing (PUAT) rapidly supports pneumococcal etiology in community-acquired pneumonia (CAP), but its impact on antimicrobial optimization in routine care remains uncertain. Objectives: To evaluate antimicrobial spectrum narrowing after positive PUAT in hospitalized adults with CAP and to describe other antimicrobial optimization actions. Methods: We conducted a retrospective observational cohort study at a Portuguese tertiary hospital including adults hospitalized with CAP and positive PUAT between January 2020 and December 2024. The primary endpoint was antimicrobial spectrum narrowing. Absence or early discontinuation of atypical coverage and intravenous-to-oral switch were analyzed separately. Results: Among 332 episodes, antimicrobial spectrum narrowing occurred in 30 (9.0%), after a median of 3 days (Q1-Q3, 2-4). De-escalation to ampicillin or amoxicillin occurred in 7 episodes (2.1%). Narrowing was less frequent among patients initially treated with amoxicillin/clavulanate (10.0% vs 43.7%; p<0.001) and more frequent among those receiving broader-spectrum beta-lactams other than ceftriaxone or amoxicillin/clavulanate (20.0% vs 6.3%; p=0.007). Absence or early discontinuation of atypical coverage occurred in 158 episodes (47.6%) and intravenous-to-oral switch in 71 (21.4%). Narrowing and intravenous-to-oral switch were associated with shorter length of stay, but these associations were considered exploratory because of potential confounding by clinical stability. Conclusions: In hospitalized PUAT-positive CAP, antimicrobial spectrum narrowing was uncommon, whereas atypical coverage optimization was the most frequent prescribing change. Structured reassessment pathways may be needed to translate PUAT results into safe, microbiology-guided antimicrobial optimization.